← Browse by Condition
Medical Condition
advanced solid tumors
Total Trials
27
Recruiting Now
27
Trial Phases
Phase 1, Phase 1, Phase 2
NCT07310134 Phase 1
Recruiting
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Enrollment
80 pts
Location
China
Sponsor
Nanjing Zenshine Pharmaceutica...
NCT06907628 Phase 1
Recruiting
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Enrollment
150 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
NCT05473624 Phase 1
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Enrollment
153 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co., ...
NCT05836324 Phase 1
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Enrollment
408 pts
Location
United States, Denma...
Sponsor
Incyte Corporation
NCT06736327 Phase 1
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm...
NCT05944224 Phase 1, Phase 2
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Enrollment
63 pts
Location
China
Sponsor
Shanghai Pharmaceuticals Holdi...
NCT07349537 Phase 1
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Enrollment
574 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT06443489 Phase 1
Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
Enrollment
80 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
NCT07359066 Phase 1, Phase 2
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Enrollment
210 pts
Location
China
Sponsor
Shanghai SciBrunch Therapeutic...
NCT06686745 Phase 1
Recruiting
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Enrollment
130 pts
Location
China
Sponsor
Jiangsu Simcere Pharmaceutical...
NCT06376136 Phase 1, Phase 2
Recruiting
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Enrollment
216 pts
Location
China
Sponsor
Bio-Thera Solutions
NCT06368960 Phase 1
Recruiting
BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment
36 pts
Location
China
Sponsor
InnoBM Pharmaceuticals Co., Lt...
NCT05881525 Phase 1
Recruiting
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
TCRCure Biopharma Ltd.
NCT06314373 Phase 1, Phase 2
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
Enrollment
243 pts
Location
China
Sponsor
Xizang Haisco Pharmaceutical C...
NCT05853367 Phase 1
Recruiting
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Enrollment
178 pts
Location
United States, Canad...
Sponsor
Merck Sharp & Dohme LLC
NCT06840821 Phase 1, Phase 2
Recruiting
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Enrollment
156 pts
Location
China
Sponsor
Mainline Biosciences (Shanghai...
NCT06299839 Phase 1
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
Enrollment
48 pts
Location
United States, Bulga...
Sponsor
Pasithea Therapeutics Corp.
NCT06615193 Phase 1
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Enrollment
111 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar...
NCT07285395 Phase 1
Recruiting
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
Enrollment
12 pts
Location
China
Sponsor
The Affiliated Hospital of Xuz...
NCT06968572 Phase 1
Recruiting
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
Enrollment
245 pts
Location
China
Sponsor
Haisco Pharmaceutical Group Co...
NCT06158477 Phase 1
Recruiting
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Enrollment
75 pts
Location
China
Sponsor
Chengdu JOYO pharma Co., Ltd.
NCT06697197 Phase 1, Phase 2
Recruiting
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Enrollment
413 pts
Location
United States, Belgi...
Sponsor
Bristol-Myers Squibb
NCT06818643 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Enrollment
270 pts
Location
United States, Chile...
Sponsor
Merck Sharp & Dohme LLC
NCT05592626 Phase 1, Phase 2
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Enrollment
365 pts
Location
United States, Canad...
Sponsor
Marengo Therapeutics, Inc.
NCT06840886 Phase 1
Recruiting
A Study of PHST001 in Advanced Solid Tumors
Enrollment
155 pts
Location
United States
Sponsor
Pheast Therapeutics
NCT07252414 Phase 1
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Changchun GeneScience Pharmace...
NCT07164950
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
Enrollment
58 pts
Location
China
Sponsor
Sheng Zhang